Highlights of WCTRIMS 2008 Montreal, Quebec, Canada September 17-20, 2008

• Research into the efficacy and safety of oral therapies for multiple sclerosis (MS), including fingolimod and laquinimod.
• Data that suggest a role in the preservation of neural tissue by BG00012
• Several studies on ibudilast's effect on the development of black holes and its potential neuroprotective effects.
• Results from multiple clinical trials, including rituximab in primary-progressive MS and alemtuzumab in relapsing-remitting MS.
• Reports on the efficacy of glatiramer acetate (GA) taken every other day and of short-term induction therapy with mitoxantrone prior to treatment with GA.
• Data demonstrating the safety and tolerability of the peptide vaccine, ATX-MS1467, for MS.
• A proof-of-concept study for treatment with the antisense oligonucleotide, ATL1102, in RRMS.
• Multiple studies on the early treatment of clinically isolated syndrome illuminate the utility of MRI prognostic indicators, as well as the impact of disease-modifying therapy (DMT).
• Long-term clinical trial data illustrate the effectiveness of DMT over time and reveal that MRI data are predictors of long-term outcomes in patients with MS.
• New insights into pediatric MS: risk factors, disease burden at onset, and the Epstein-Barr virus' potential association.
• Findings showing the superiority of the MS Severity Scale over the Expanded Disability Status Scale score for predicting disease progression.
• Insights into the demographic predictors of early disease course and the predictive utility of genes.

	Abbreviation Key for This Issue
	Oral Therapy Study Outcomes: A Global View
	Examining Emerging Therapies & Approaches
	From CIS to Clinically Definite MS
	Results From Long-Term Clinical Trial Data
	Pediatric MS Risk Factors & Disease Characteristics
	Predicting MS Outcomes: Severity Scales, Genes, & Clinical  Features

DAILY COVERAGE

GUEST EDITOR:
Patricia K. Coyle, MD
Professor and Acting Chair of Neurology
Director, Stony Brook MS Comprehensive Care Center
Stony Brook University Medical Center
State University of New York at Stony Brook
Stony Brook, New York 

Neura On-Site coverage of the World Congress on Treatment and Research in Multiple Sclerosis (WCTRIMS) held in Montreal, Canada on September 17-20, 2008.